Loading
A study of 67,278 patients whose tumours had both RNA and DNA sequencing, showing that RNA found a fifth more of the gene fusions that matched drugs target.
Concurrent RNA and DNA sequencing increased detection of driver gene fusions by 21 per cent compared with DNA sequencing alone, and 29 per cent of fusions detected were outside an FDA-approved indication. The full text describes Tempus xR as a whole-transcriptome RNA sequencing assay; the authors are Tempus staff.
A tumour DNA test alone misses some fusions that have a matched drug.
Shares Biomarker, RNA sequencing & expression profiling, Comprehensive genomic profiling.
Shares Tempus xR, RNA sequencing & expression profiling, Comprehensive genomic profiling.
Shares RNA sequencing & expression profiling, Comprehensive genomic profiling.
Shares RNA sequencing & expression profiling, Comprehensive genomic profiling.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/